Ovid Therapeutics Inc. (OVID)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q3 '20: 6.9M Q4 '20: 5.7M Q1 '21: 208.4M Q2 '21: 0 Q3 '21: 0 Q4 '21: 0 Q1 '22: 1.4M Q2 '22: 0 Q3 '22: 11.1K Q4 '22: 46.3K Q1 '23: 66K Q2 '23: 75K Q3 '23: 109K Q4 '23: 142K Q1 '24: 148K Q2 '24: 169K Q3 '24: 173K Q4 '24: 76K Q1 '25: 130K Q2 '25: 6.3M Q3 '25: 132K Q4 '25: 718K Q1 '26: 0 Q2 '26: 733K Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-70M 0 70M 140M 210M Q1 '16: -3.7M Q2 '16: -5.4M Q3 '16: -5.8M Q4 '16: -7.6M Q1 '17: -34.3M Q2 '17: -10.3M Q3 '17: -9.4M Q4 '17: -11M Q1 '18: -13.4M Q2 '18: -13.2M Q3 '18: -13.2M Q4 '18: -13.1M Q1 '19: -14.1M Q2 '19: -13.3M Q3 '19: -16.8M Q4 '19: -17.3M Q1 '20: -20.3M Q2 '20: -23.1M Q3 '20: -16.4M Q4 '20: -21.6M Q1 '21: 176.6M Q2 '21: -14.3M Q3 '21: -11.7M Q4 '21: -26.4M Q1 '22: -16.3M Q2 '22: -14.3M Q3 '22: -12.8M Q4 '22: -12.2M Q1 '23: -14.9M Q2 '23: -14.2M Q3 '23: -12M Q4 '23: -18.2M Q1 '24: -17.4M Q2 '24: -20.5M Q3 '24: -13.2M Q4 '24: -10.7M Q1 '25: -12.6M Q2 '25: -5.1M Q3 '25: -12.5M Q4 '25: -12.3M Q1 '26: -17.8M Q2 '26: -15.7M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income Quarterly

-60M 0 60M 120M 180M Q1 '16: -3.7M Q2 '16: -5.4M Q3 '16: -5.8M Q4 '16: -7.6M Q1 '17: -34.2M Q2 '17: -10.2M Q3 '17: -9.4M Q4 '17: -11M Q1 '18: -13.2M Q2 '18: -12.9M Q3 '18: -13M Q4 '18: -12.9M Q1 '19: -13.8M Q2 '19: -13.1M Q3 '19: -16.6M Q4 '19: -17M Q1 '20: -20M Q2 '20: -22.6M Q3 '20: -16.4M Q4 '20: -22M Q1 '21: 176M Q2 '21: -15.8M Q3 '21: -11.4M Q4 '21: -26M Q1 '22: -16.1M Q2 '22: -14.6M Q3 '22: -12M Q4 '22: -11.5M Q1 '23: -13.4M Q2 '23: -12.4M Q3 '23: -11.3M Q4 '23: -15.3M Q1 '24: -11.7M Q2 '24: 8.5M Q3 '24: -14M Q4 '24: -9.3M Q1 '25: -10.2M Q2 '25: -4.7M Q3 '25: -12.2M Q4 '25: 9.7M Q1 '26: -17M Q2 '26: -15M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M 0 60M 120M 180M Q1 '16: -3.8M Q2 '16: -3.6M Q3 '16: -4.6M Q4 '16: -5.7M Q1 '17: -7.2M Q2 '17: -6M Q3 '17: -9.3M Q4 '17: -9M Q1 '18: -12.9M Q2 '18: -11.6M Q3 '18: -10M Q4 '18: -11M Q1 '19: -12.9M Q2 '19: -11.8M Q3 '19: -9.5M Q4 '19: -16.9M Q1 '20: -18.4M Q2 '20: -17.2M Q3 '20: -1.5M Q4 '20: -14.5M Q1 '21: 160.9M Q2 '21: -19.4M Q3 '21: -10.9M Q4 '21: -12M Q1 '22: -20.1M Q2 '22: -13.3M Q3 '22: -12.7M Q4 '22: -9.2M Q1 '23: -12.1M Q2 '23: -11.7M Q3 '23: -10.1M Q4 '23: -11.9M Q1 '24: -16.7M Q2 '24: -14.3M Q3 '24: -15M Q4 '24: -10M Q1 '25: -10.3M Q2 '25: -4.8M Q3 '25: -12.9M Q4 '25: -10.4M Q1 '26: -13.9M Q2 '26: -17.6M Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow Quarterly

-60M 0 60M 120M 180M Q1 '16: -3.9M Q2 '16: -3.6M Q3 '16: -4.6M Q4 '16: -5.7M Q1 '17: -7.2M Q2 '17: -6M Q3 '17: -9.3M Q4 '17: -9M Q1 '18: -12.9M Q2 '18: -11.6M Q3 '18: -10.1M Q4 '18: -11M Q1 '19: -12.9M Q2 '19: -11.8M Q3 '19: -9.5M Q4 '19: -16.9M Q1 '20: -18.4M Q2 '20: -17.2M Q3 '20: -1.5M Q4 '20: -14.6M Q1 '21: 160.9M Q2 '21: -19.4M Q3 '21: -10.9M Q4 '21: -12.2M Q1 '22: -20.1M Q2 '22: -14.3M Q3 '22: -12.7M Q4 '22: -9.3M Q1 '23: -12.1M Q2 '23: -11.7M Q3 '23: -10.1M Q4 '23: -11.9M Q1 '24: -16.7M Q2 '24: -14.3M Q3 '24: -15M Q4 '24: -10M Q1 '25: -10.3M Q2 '25: -4.8M Q3 '25: -12.9M Q4 '25: -10.4M Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 54.7M Q2 '20: 55.6M Q3 '20: 59.4M Q1 '21: 66.6M Q2 '21: 67.8M Q3 '21: 67.9M Q1 '22: 70.3M Q2 '22: 70.4M Q3 '22: 70.4M Q1 '23: 70.5M Q2 '23: 70.5M Q3 '23: 70.6M Q1 '24: 70.7M Q2 '24: 71.2M Q3 '24: 71M Q1 '20 Q3 '20 Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '16: -2.28 Q1 '17: -5.39 Q2 '17: -5.41 Q3 '17: -5.20 Q4 '17: -4.88 Q1 '18: -1.94 Q2 '18: -1.90 Q3 '18: -2.05 Q4 '18: -2.12 Q1 '19: -2.04 Q2 '19: -1.85 Q3 '19: -1.75 Q4 '19: -1.58 Q1 '20: -1.49 Q2 '20: -1.56 Q3 '20: -1.41 Q4 '20: -1.41 Q1 '21: 1.49 Q2 '21: 1.67 Q3 '21: 1.78 Q4 '21: 1.76 Q1 '22: -1.00 Q2 '22: -0.98 Q3 '22: -0.98 Q4 '22: -0.77 Q1 '23: -0.73 Q2 '23: -0.70 Q3 '23: -0.69 Q4 '23: -0.75 Q1 '24: -0.73 Q2 '24: -0.43 Q3 '24: -0.47 Q3 '17 Q3 '18 Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.